Publications: Hong-Ming Hu, Ph.D.

Chief, Laboratory of Cancer Immunology
Robert W. Franz Cancer Research Center

To view related abstracts of these publications, search the PubMed database.

1. Laherty CD*, Hu H-M*, Opipari, AW, Wang F and Dixit VM. 1992. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by Activating NF-kB, J. Biol. Chem. 267:24157-24160,1992.
    *equal contributors
2. Opipari Jr. AW, Hu H-M, Yabkowitz R and Dixit VM. The A20 Zinc finger protein protects cells from Tumor Necrosis Factor Cytotoxicity. J. Biol. Chem. 267:12424-12427,1992.
3. Hu H-M, O’Rourke K, Boguski MS, and Dixit VM. A novel Ringer Finger protein interacts with the cytoplasmic domain of CD40. J. Biol. Chem. 269:30069-30072,1994.
4. Zhang Y, Hu H-M, Cai R, Feng Y-M et al. Secretory expression of a single-chain insulin precursor in yeast and its conversion into human insulin. Sci. China C Life Sci. 39(3):225-33,1996.
5. Hu, H-M, and Fox, BA. Transfer of Genes Encoding Antigens, Co-Stimulatory Molecules, or Adhesion/Accessory Molecules as a Strategy to Augment the Anti-Tumor Immune Response.  Gene Therapy of Cancer.  ed.  Brenner, M.K. and Moen, R.C. Marcel Dekker Inc. New York, pg 121-138, 1996.
6. Fox BA, Drury M, Hu H-M, Huntzicker EG, Cao Z, Qie W and Urba WJ: Lipofection indirectly increases expression of endogenous MHC class I molecules on tumor cells.  Cancer Gene Therapy 5:307-312, 1998.
7. Hu H-M, Urba WJ, and Fox BA: Gene modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to type 1 cytokine profile.  J. Immunol. 161:3033-3041,1998.
8. Chu, Y, Hu, H-M, Winter, H et al: Examining the immune response in sentinel lymph nodes of mice and men., Eur J Nucl Med, 26(4 Suppl):S50-53, 1999.
9. Winter H, Hu H-M, Urba WJ, Fox BA: Tumor regression after adoptive transfer of effector-T cells is independent of perforin or Fas-Ligand (APO-1L/CD95L). J. Immunol. 163:4462-4472,1999.
10. Hu H-M, Winter H, Urba WJ, and Fox BA: Divergent Roles for CD4+ Helper T Cells in the Priming and Effector Phases of Adoptive Immunotherapy. J. Immunol. 165:4246-4253, 2000.
11. Winter H, Hu H-M, Urba WJ and Fox BA: Immunotherapy of Melanoma: A Dichotomy between the Requirement for IFN- in Vaccine Induced Antitumor Immunity, versus Adoptive Immunotherapy.  J. Immunol. 166:7370-7380, 2001.
12. Meijer SL, Dols A, Hu H-M, Jensen S, Poehlein CH, Chu Y, Winter H, Yamada J, Moudgil T, Wood WJ, Doran T, Justice L, Fisher B, Wisner P, Wood J, Vetto JT, Mehrotra R, Rosenheim S, Weinberg AD, Bright R, Walker E, Puri R, Smith JW 2nd, Urba WJ, Fox BA. Immunological and molecular analysis of the sentinel lymph node: a potential approach to predict outcome, tailor therapy, and optimize parameters for tumor vaccine development. J Clin Pharmacol. 2001 Jul; Suppl: 81S-94S.
13. Meijer SL, Dols A, Urba WJ, Hu H-M, et al: Adoptive Cellular Therapy with Tumor Vaccine Draining Lymph Node Lymphocytes following Vaccination with HLA-B7/β2-microgloblulin Gene-Modified Autologous Tumor Cells. J. Immunotherapy. 25:359-372. 2002.
14. Hu H-M, Poehlein CH, Urba WJ, and Fox BA: Augmented antitumor immune responses in reconstituted lymphopenic hosts. Cancer Research. 62:3914-1919 2002.
15. Hu H-M, Winter H, Ma J, Croft M, Urba WJ, and Fox BA: CD28, TNF and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8+ T cells. J. Immunol.169: 4897-4904. 2002.
16. Dols A, Meijer SL, Hu H-M, Walter J. Urba, et al: Identification of Tumor-Specific Antibodies in Patients with Breast Cancer Vaccinated with Gene-Modified Allogeneic Tumor cells. J. Immunotherapy. 26(2):163–170. 2003.
17. Poehlein CH, Hu H-M, Yamada J, Assmann I, Alvord G, Urba WJ, and Fox BA. TNF Plays an Essential Role in Tumor Regression after Adoptive Transfer of Perforin/IFN-γ Double Knockout Effector T Cells. J. Immunol. 270: 2004-2013. 2003.
18. Jensen SM, Meijer SL, Kurt RA, Urba WJ, Hu H-M, and Fox BA. Regression of a Mammary Adenocarcinoma in STAT6-/- Mice Is Dependent on the Presence of STAT6-Reactive T Cells. J. Immunol. 270: 2014-2021. 2003.
19. Winter H*, Hu H-M*, et al: Tumor-Induced Polarization of Tumor Vaccine-Draining Lymph Node T Cells to a Type 1 Cytokine Profile Predicts Inherent Strong Immunogenicity of the Tumor and Correlates With Therapeutic Efficacy in Adoptive Transfer Studies. Immunology. 108: 409-419. 2003.
     * Equal contributor.
20. Smith JW 2nd, Walker E, Fox BA, Haley D, Wisner KP, Doran T, Fisher B, Justice, Wood WJ, L, Vetto JT, Dols A, Meijer SL, Hu H-M, Romero, P, Alvord WG, Urba WJ.  Adjuvant Immunization of HLA-A2+ melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J. Clin Onc., 21:1562-1573. 2003.
21. Ruttinger D, Li R, Urba WJ, Fox BA, Hu H-M: Evaluation of a preclinical model of bone metastasis for the study of an adoptive immunotherapy. Eur. Surg. Res. 35(4):246-51. 2003.
22. Ma J, Urba WJ, Si L, Wang Y, Fox BA, Hu H-M: Enhanced Protective Anti-Tumor Immunity in Mice Subjected to Sublethal Irradiation and Immune Reconstitution. Eur. J. Immunol. 33:2123-2132. 2003.
23. Dols A, Smith II JW, Meijer SL, Fox, BA, Hu H-M, Walker E, Rosenheim S, Moudgil T, Doran T, Wood W, Seligman M, Alvord WG, Schoof D, and Urba WJ. Vaccination of Women with Metastatic Breast Cancer, Using a Costimulatory Gene (CD80)-Modified, HLA-A2-Matched, Allogeneic, Breast Cancer Cell Line: Clinical and Immunological Results. Human Gene Therapy. 14:1117-1123, 2003.
24. Hu H-M, Dols A, Meijer SL, Walker E, Urba WJ, and Fox BA: Immunological monitoring of peptide vaccination in melanoma patients using soluble peptide/HLA-A2 dimer complexes. J. Immunotherapy. 27(1):48-59. 2004.
25. Li R, Ruttinger D, Urba WJ, Fox BA, and Hu H-M: Targeting and Amplification of Tumor Immune Killing Mechanisms by Pro-Smac. International J. of Cancer. 109(1):85-94. 2004.
26. Walker E, Haley D, Miller W, Floyd K, Wisner KP, Sanjuan N, Maecker H, Romero P, Hu H-M, Alvord WG, Smith JW 2nd, Fox BA, and Urba WJ. Functional and Phenotype Analysis of Memory/Effector CD8+ T cells from HLA-A2+ Early Stage Melanoma Patients Immunized with a Modified gp100209-2M Peptide. Clin. Can. Res. 10(2): 668-80. 2004.
27. Meijer SL, Dols A, Hu H-M, Chu Y, Romero P, Urba WJ, Fox BA. Reduced L-selectin (CD62L(Low)) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine. Cell Immunol. 227(2): 93-102. 2004. 
28. Ruttinger D, Li R, Urba WJ, Fox BA, and Hu H-M. Regression of bone metastases following adoptive transfer of anti-CD3-activated and IL-2-expanded tumor vaccine draining lymph node cells. Clinical and Experimental Metastases.  21(4):305-312, 2004.
29. Ma J, Poehlein, Jensen SM, Lacelle MG, Moudgil TM, Ruttinger D, Haley D, Goldstein, Smith III JW, Curti B, Ross H, Walker E, Hu H-M, Urba, WJ and Fox BA. Manipulating the host response to autologous tumor vaccines. Brown F, Petricciani J (eds): Development of Therapeutic Cancer Vaccines. Dev Biol. (116): 93-107, 2005.
30. Hu, H-M, Chu, Y, Urba, W.J. Undefined-antigen vaccines. Samir Kheif (eds): Tumor Immunology and Cancer Vaccines. Cancer Treatment and Research, Series Editor, Rosen ST,  Kluwer Academic Publishers. New York, 121: 207-226, 2005. 
31. Li R, Moudgil T, Ross HJ, and Hu H-M. The BH3-only Proapoptotic Protein Bim Links the Microtubule Poison Paclitaxel to the Mitochondrial Damage and Apoptosis. Cell Death and Differentiation. (2005). 12(3): 292-303.
32. Poehlein, C. H., Ruttinger, D., Ma, J., 1. Laherty CD*, Hu H-M*, Opipari, AW, Wang F and Dixit VM. 1992. , Urba, W. J., and Fox, B. A.  Immunotherapy for melanoma: the good, the bad, and the future. Curr Oncol Rep. 7, 383-392. (2005).
33. Wang, L. X., Li, R., Yang, G., Lim, M., O'Hara, A., Chu, Y., Fox, B. A., Restifo, N. P., Urba, W. J., and Hu, H. M. (2005). Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res 65, 10569-10577.
34. Chu, Y., Wang, L. X., Yang, G., Xiong, S., Ross H.J., Prell, R., Urba, W. J., and Hu, H-M., (2006). Efficacy of GM-CSF-producing Tumor Vaccine after Docetaxel Chemotherapy in Mice Bearing Established Lewis Lung Carcinoma. J. Immunother. 29(4):367-80.
35. He, H, Wisner, P, Yang, G, Hu, HM, Haley, D, Miller, W, O’Hara, A, Alvord, WG, Clegg, CH, Fox, BA, Urba, WJ, Walker, EB: (2006) Combined IL-2 and Low-Dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J Translational Medicine. 4:24.
36. Kuriyama, H., Watanabe, S., Kjaergaard, J., Tamai, H., Zheng, R., Weinberg, A. D., Hu, H.M. et al. (2007). Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination. Cell Immunol. (2006) 243:30-40.
37. Winter H, van den Engel N., Poehlein C.,Hatz R., Fox B.A. and Hu, H.M. (2007). Tumor-specific T cells signal tumor destruction via the lymphotoxin β receptor. J Translational Medicine, 5:14.
38. Morris, NP, Peters, C, Montler, R, Hu, HM, Curti, BD, Urba, WJ, Weinberg, AD. 2007. Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled coil trimerization domain. Molecular Immunology.
39. Meijer, S.L., Dols, A., Jensen, S.M., Hu, H.M., Miller, W., Walker, E.D., Romero, P., Fox, B.A., and Urba, W.J. 2007. Induction of circulating tumor-reactive CD8+ T cells following vaccination of melanoma patients with the gp100 209-2M peptide. J. Immunother. In press.